Abstract #0369
1 H MRS detection of glutamate predicts survival in pediatric medulloblastoma
Martin Wilson 1,2 , Simrandip K Gill 1,2 , Lesley MacPherson 2 , Martin English 2 , Theodoros N Arvanitis 2,3 , and Andrew C Peet 1,2
1
School of Cancer Sciences, University of
Birmingham, Birmingham, United Kingdom,
2
Birmingham
Children's Hospital NHS Foundation Trust, Birmingham,
United Kingdom,
3
Institute
of Digital Healthcare, WMG, University of Warwick,
Coventry, United Kingdom
Medulloblastoma is the most common malignant brain
tumour occurring in childhood and the diversity of
outcomes makes this a particularly challenging disease
to treat. In this study,
1
H
MRS was collected from 35 medulloblastoma patients and
metabolite biomarkers were investigated to stratify
high-risk patients. Glutamate was found to predict
survival, and validated prospectively.
1
H
HR-MAS was collected from a sub-set of patients and
agreement between in-vivo and ex-vivo results was found,
adding validation to the assignment of glutamate. The
identification of glutamate as a predictive biomarker of
survival in medulloblastoma provides a clinically viable
measure and multi-center reproduction is warranted.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
